Data shows Pfizer’s RSV vaccine given to pregnant mothers as a single dose in the late second or third trimester is effective at protecting newborns, the company said. In the first 90 days of the baby’s life, the vaccine was 81% effective at preventing severe lower respiratory tract infections that require hospitalization or assisted breathing, Pfizer said.